Hospital pharmacies held the dominant position in the invasive ductal carcinoma treatment market in 2025, accounting for a 47.2% share. Their leadership is maintained through the clinical nature of invasive ductal carcinoma treatment, where therapy selection, dosing, and dispensing are closely tied to hospital-based oncology care pathways. Patients receiving complex regimens often obtain medicines directly through hospital systems because treatment administration, prescription control, and specialist oversight are concentrated there, which reinforces the dominant share of hospital pharmacies in this market.

Online pharmacies are emerging as the fastest-growing distribution channel in the invasive ductal carcinoma treatment market as patient preference shifts toward more convenient refill access and home-based medicine procurement where clinically appropriate. Growth is being supported by the increasing use of longer-term oral treatment protocols and follow-up care outside acute hospital settings, which makes digital dispensing models more practical than traditional channels for certain patients. Compared with offline alternatives, online pharmacies are gaining momentum because they align better with convenience, continuity, and remote access needs during extended treatment journeys.

Type Segment Analysis: Hormone Receptor-positive (Largest Segment) vs HER2-positive (Fastest-Growing Segment)

In 2025, Hormone Receptor-positive represented the largest type segment in the invasive ductal carcinoma treatment market, with a 63.37% share. This leadership reflects the broad treatment applicability of this disease subtype within routine oncology practice, where established therapeutic pathways support sustained use across a large patient population. Its dominant share is maintained by the fact that hormone receptor-based classification directly guides long-duration treatment planning, making this segment a central part of care delivery in the invasive ductal carcinoma treatment market.

HER2-positive is the fastest-growing type segment in the invasive ductal carcinoma treatment market due to the expanding treatment focus on biologically defined disease management and subtype-specific therapeutic approaches. Growth in this segment is being driven by stronger clinical adoption of targeted treatment pathways for patients identified through biomarker testing, which increases the practical relevance of HER2-positive classification in treatment decisions. Relative to broader conventional approaches, HER2-positive care is gaining momentum because it is closely linked to more specialized and increasingly differentiated treatment selection.